Lexaria Bioscience Q2 EPS $(0.06) Beats $(0.11) Estimate, Sales $20.000K Miss $100.000K Estimate
Benzinga Newsdesk 7 months ago
EarningsEarnings BeatsEarnings MissesNews
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 60 percent increase over losses of $(0.15) per share from
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 60 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $20.000 thousand which missed the analyst consensus estimate of $100.000 thousand by 80.00 percent. This is a 88.51 percent decrease over sales of $174.000 thousand the same period last year.